{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:48:28Z","timestamp":1778795308614,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1124\/jpet.118.250225","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T21:25:18Z","timestamp":1541453118000},"page":"79-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib"],"prefix":"10.1016","volume":"368","author":[{"given":"Yoo-Kyung","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunseok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungwoo","family":"Hyung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-Seong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wooin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suk-Jae","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.118.250225_bib1","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2174\/138161211797440186","article-title":"Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up","volume":"17","author":"Agarwal","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1124\/jpet.118.250225_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/jpet.110.167601","article-title":"Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux","volume":"334","author":"Agarwal","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.250225_bib3","first-page":"417","article-title":"Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C","volume":"1","author":"Allen","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.118.250225_bib4","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.118.250225_bib5","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/bmc.874","article-title":"Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography","volume":"21","author":"de Vries","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/jpet.118.250225_bib6","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1002\/jps.22674","article-title":"Development of a new permeability assay using low-efflux MDCKII cells","volume":"100","author":"Di","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.118.250225_bib7","doi-asserted-by":"crossref","first-page":"12670","DOI":"10.1038\/srep12670","article-title":"BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to olaparib","volume":"5","author":"Dufour","year":"2015","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.118.250225_bib8","series-title":"Committee for Medicinal Products for Human Use Assessment Report: Lynparza","year":"2014"},{"key":"10.1124\/jpet.118.250225_bib9","series-title":"FDA Guidance for Industry: Bioanalytical Method Validation","year":"2013"},{"key":"10.1124\/jpet.118.250225_bib10","series-title":"In Vitro Metabolism and Transporter Mediated Drug-Drug Interaction Studies: Guidance for Industry","year":"2017"},{"key":"10.1124\/jpet.118.250225_bib11","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1007\/s11095-014-1599-5","article-title":"Genomic knockout of endogenous canine P-glycoprotein in wild-type, human P-glycoprotein and human BCRP transfected MDCKII cell lines by zinc finger nucleases","volume":"32","author":"Gartzke","year":"2015","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.118.250225_bib12","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/jps.23901","article-title":"Establishment of optimized MDCK cell lines for reliable efflux transport studies","volume":"103","author":"Gartzke","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.118.250225_bib46","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1517\/17425255.4.6.721","article-title":"Utilization of membrane vesicle preparations to study drug\u2013ABC transporter interactions","volume":"4","author":"Glavinas","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/jpet.118.250225_bib13","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0006-2952(02)01355-2","article-title":"Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man","volume":"64","author":"Goh","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.118.250225_bib14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/jphp.12799","article-title":"The conditional stimulation of rat organic cation transporter 2, but not its human ortholog, by mesoridazine: the possibility of the involvement of the high-affinity binding site of the transporter in the stimulation","volume":"69","author":"Hyung","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/jpet.118.250225_bib15","first-page":"F84","article-title":"Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells","volume":"277","author":"Ito","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.118.250225_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2017.01.026","article-title":"Estimation of the minimum permeability coefficient in rats for perfusion-limited tissue distribution in whole-body physiologically-based pharmacokinetics","volume":"115","author":"Jeong","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1124\/jpet.118.250225_bib17","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1016\/j.xphs.2017.04.018","article-title":"A CRISPR-Ccas9 generated MDCK cell line expressing human MDR1 without endogenous canine MDR1 (cABCB1): an improved tool for drug efflux studies","volume":"106","author":"Karlgren","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.118.250225_bib18","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/j.1476-5381.2010.00801.x","article-title":"Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport","volume":"160","author":"Kuteykin-Teplyakov","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.118.250225_bib19","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1124\/jpet.118.250225_bib20","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/jps.24378","article-title":"Kinetics of the absorption, distribution, metabolism, and excretion of lobeglitazone, a novel activator of peroxisome proliferator-activated receptor gamma in rats","volume":"104","author":"Lee","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.118.250225_bib21","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1128\/AAC.01089-12","article-title":"Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro","volume":"56","author":"Lepist","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.118.250225_bib22","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/jps.23523","article-title":"Kinetic analysis of human and canine P-glycoprotein-mediated drug transport in MDR1-MDCK cell model: approaches to reduce false-negative substrate classification","volume":"102","author":"Li","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.118.250225_bib23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/PL00000912","article-title":"From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance","volume":"58","author":"Litman","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"10.1124\/jpet.118.250225_bib24","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1083\/jcb.117.4.787","article-title":"Transfection of nonmuscle beta- and gamma-actin genes into myoblasts elicits different feedback regulatory responses from endogenous actin genes","volume":"117","author":"Lloyd","year":"1992","journal-title":"J Cell Biol"},{"key":"10.1124\/jpet.118.250225_bib25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/dmd.30.7.763","article-title":"Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.118.250225_bib26","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/00498254.2016.1241449","article-title":"In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib","volume":"47","author":"McCormick","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.118.250225_bib45","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","article-title":"Rational use of in vitro P-glycoprotein assays in drug discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.250225_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/13543784.2017.1318847","article-title":"Olaparib for the treatment of breast cancer","volume":"26","author":"Robert","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.118.250225_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2015.01.015","article-title":"The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2)","volume":"93","author":"R\u00f6mermann","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.118.250225_bib29","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.118.250225_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V99.2.507","article-title":"The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors","volume":"99","author":"Scharenberg","year":"2002","journal-title":"Blood"},{"key":"10.1124\/jpet.118.250225_bib31","first-page":"5269","article-title":"Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies","volume":"60","author":"Scheffer","year":"2000","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.118.250225_bib32","first-page":"2628","article-title":"Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies","volume":"51","author":"Schinkel","year":"1991","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.118.250225_bib33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ejpb.2007.03.017","article-title":"Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines","volume":"67","author":"Siissalo","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1124\/jpet.118.250225_bib34","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0022-3549(15)00171-9","article-title":"Complete knockout of endogenous Mdr1 (Abcb1) in MDCK cells by CRISPR-Cas9","volume":"105","author":"Simoff","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.118.250225_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal Biochem"},{"key":"10.1124\/jpet.118.250225_bib36","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jchromb.2011.05.003","article-title":"Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma","volume":"879","author":"Sparidans","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/jpet.118.250225_bib37","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0022-3565(24)38782-8","article-title":"Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia","volume":"296","author":"Stephens","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.250225_bib38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1023\/A:1016140429238","article-title":"Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?","volume":"19","author":"Tang","year":"2002","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.118.250225_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0928-0987(02)00015-5","article-title":"Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I-IV","volume":"15","author":"Taub","year":"2002","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/jpet.118.250225_bib40","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/dmd.105.005421","article-title":"Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity","volume":"33","author":"Taub","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.118.250225_bib41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.118.250225_bib42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijpharm.2004.10.007","article-title":"Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier","volume":"288","author":"Wang","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1124\/jpet.118.250225_bib43","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1124\/dmd.104.003442","article-title":"Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells","volume":"33","author":"Xia","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.118.250225_bib44","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.116.074120","article-title":"Specific inhibition of the distribution of lobeglitazone to the liver by atorvastatin in rats: evidence for a rat organic anion transporting polypeptide 1B2-mediated interaction in hepatic transport","volume":"45","author":"Yim","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.118.250225_bib47","series-title":"ADME-enabling technologies in drug design and development","author":"Zhang","year":"2012"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524260183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524260183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.118.250225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T16:01:14Z","timestamp":1739980874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524260183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0022356524260183"],"URL":"https:\/\/doi.org\/10.1124\/jpet.118.250225","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.118.250225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}